https://www.neudirection.com/neu-001-for-amblyopia-treatment-secures-fda-approval-for-clinical-trials/2025-09-05T11:22:10+08:00https://www.neudirection.com/crmh-hosts-international-symposium-on-advancing-amblyopia-therapies-in-hong-kong/2025-09-10T18:44:38+08:00https://www.neudirection.com/neudirection-limited-celebrates-nmpa-clinical-trial-approval-for-neu-001-to-treat-amblyopia/2025-06-04T17:35:45+08:00https://www.neudirection.com/successful-dosing-of-first-subject-in-phase-i-clinical-trial-for-our-first-in-class-amblyopia-drug-neu-001/2025-09-09T17:51:06+08:00https://www.neudirection.com/groundbreaking-discovery-in-cell-neudirection-limiteds-lead-asset-neu-001-demonstrates-new-potential-for-alzheimers-disease-treatment/2026-02-12T17:28:24+08:00https://www.neudirection.com/neudirections-neu-001-successfully-completes-phase-i-clinical-trial/2026-02-25T11:23:08+08:00https://www.neudirection.com/ranked-no-1-neudirection-wins-excellence-award-at-the-16th-moorden-institute-accelerator-pitch-day/2026-05-25T16:45:02+08:00